Enlightify (NYSE:ENFY) Stock

Enlightify

Enlightify Inc Formerly China Green Agriculture Inc is engaged in the business of fertilizer and agricultural products. It involves the research, development, production, distribution, and sale of humic acid-based compound fertilizers, blended fertilizers, organic compound fertilizers, slow-release fertilizers, concentrated water-soluble fertilizers, and mixed organic-inorganic compound fertilizers and the development, production, and distribution of agricultural products, such as top-grade fruits, vegetables, flowers and colored seedlings in China. The company operates in four segments: Jinong (fertilizer production), Gufeng (fertilizer production), Yuxing (agricultural products production), and Antaeus (Bitcoin). All of its operations are conducted in China.

UBS analyst Jay Sole maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Neutral and raises the price target from $23 to $26.

News

Price Target

Analyst Ratings

SHOO

UBS Maintains Neutral on Steven Madden, Raises Price Target to $26

UBS analyst Mark Carden maintains Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Buy and raises the price target from $83 to $91.

UBS Maintains Buy on Sysco, Raises Price Target to $91

UBS analyst Mark Carden maintains US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) with a Buy and raises the price target from $84 to $96.

USFD

UBS Maintains Buy on US Foods Hldg, Raises Price Target to $96

UBS analyst Josh Silverstein maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Neutral and raises the price target from $40 to $42.

UBS Maintains Neutral on Range Resources, Raises Price Target to $42

Lowe's Companies&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) CEO Marvin Ellison says generative AI won't eliminate all jobs — especially those in skilled trades and customer-facing roles.
He recently argued at a business gathering that "manual and customer-facing roles…are less likely to be replaced by AI." He emphasized frontline resilience: "AI won't stop your water heater from leaking. It isn't going to respond to an electrical issue in your home," illustrating the limits of automation.
<h2 class="wp-block-heading">Skilled Trades Beat The Robots</h2>
"It's not going to respond to an electrical issue in your home," Ellison <a href="https://www.youtube.com/watch?v=60tbjOKw1zs&amp;t=118s">said</a> in June at the Business Roundtable CEO Workforce Forum. He urged early-career workers to "stay as close to the cash register as you can — stay close to the customers." The point was clear: When a pipe bursts, human skill still matters more than artificial intelligence.
Don't Miss:
<ul class="wp-block-list">
<li>7,000+ investors have joined Timeplast's mission to eliminate microplastics—now it's your turn to <a href="https://www.benzinga.com/money/timeplast-advertorial">invest in the future of sustainable plastic before time runs out.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
To address that challenge, the Business Roundtable <a href="https://www.businessroundtable.org/business-roundtable-launches-new-workforce-initiative-to-strengthen-talent-pipelines-for-skilled-trades">named</a> Ellison and Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) CEO David Gitlin as co-chairs of a skilled trades initiative unveiled in June. The plan shares training playbooks and K-12 outreach across 150 companies, tackling a talent gap that leaves about 20 openings for each qualified welder, plumber, or line worker.
<h2 class="wp-block-heading">Numbers Signal A Shortfall</h2>
Federal data backs him up. The<a href="https://www.bls.gov/ooh/construction-and-extraction/"> Bureau of Labor Statistics</a> projects employment for electricians to jump 11% between 2023 and 2033. Plumbers and roofers each log 6% growth, while construction laborers rise 7%.&nbsp;
The agency <a href="https://www.bls.gov/ooh/construction-and-extraction/electricians.htm">estimates</a> about 80,200 electrician openings each year, driven largely by retirements — proof that machines still need power and pipes.
Trending: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a>
Demand is already spilling into entry-level hiring. <a href="https://www.linkedin.com/pulse/linkedin-grads-guide-2025-jobs-industries-cities-rise-new-ggnje">LinkedIn's</a> "Grad Guide 2025: The Jobs, Industries and Cities on the Rise for New Grads," shows construction, utilities, and oil, gas and mining leading growth for new bachelor's graduates.
Between 2022 to 2032, a McKinsey <a href="https://www.mckinsey.com/capabilities/people-and-organizational-performance/our-insights/tradespeople-wanted-the-need-for-critical-trade-skills-in-the-us">analysis</a> finds that annual hiring for essential skilled roles will need to be more than 20 times the projected annual increase in net new jobs — a churn rate no chatbot can solve alone.
<h2 class="wp-block-heading">New Money, New Pipeline</h2>
Corporate checks are arriving. The<a href="https://corporate.lowes.com/newsroom/press-releases/lowes-foundation-announces-50-million-gable-grants-program-help-meet-growing-demand-skilled-tradespeople-03-02-23"> Lowe's Foundation</a> earmarked $50 million in Gable Grants to prepare 50,000 tradespeople by 2027, saying the funding "is vital to address America's workforce shortage." Business Roundtable firms <a href="https://www.businessroundtable.org/business-roundtable-launches-new-resource-to-strengthen-employer-educator-partnerships-and-fill-in-demand-jobs">plan to pair</a> that cash with shared curricula and community college partnerships to match supply with demand, in an update to its 2018 Workforce Partnership Initiative.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
Yet AI's trajectory remains contested. Anthropic CEO Dario Amodei <a href="https://www.axios.com/2025/05/28/ai-jobs-white-collar-unemployment-anthropic">said</a> in May that the technology could erase 50% of entry‑level office roles and push unemployment to between 10% and 20%.&nbsp;
"We have yet to see any evidence of mass replacement," Brad Lightcap, chief operating officer of OpenAI, <a href="https://www.youtube.com/watch?v=jdNwzYMtPN8">said</a> on the "Hard Fork" podcast. Meanwhile, BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) CEO Larry Fink <a href="https://www.youtube.com/watch?v=R-cLxFOo7xg">said</a> at CERAWeek in March that the U.S. could "run out of electricians,"<a href="https://www.reuters.com/markets/us/blackrock-ceo-fink-says-nationalistic-policies-will-stoke-inflation-2025-03-10/"> </a>underscoring a gap robots cannot fill.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

CARR

"AI Won't Stop Your Water Heater From Leaking" : Lowe's CEO Says Skilled Trades Are Gen Z's Job Security Hack

UBS analyst Brian Meredith maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Neutral and raises the price target from $250 to $265.

UBS Maintains Neutral on RenaissanceRe Holdings, Raises Price Target to $265

Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) has outperformed the market over the past 10 years by 8.99% on an annualized basis producing an average annual return of 20.75%. Currently, Sprouts Farmers Market has a market capitalization of $15.62 billion. 
Buying $100 In SFM: If an investor had bought $100 of SFM stock 10 years ago, it would be worth $668.06 today based on a price of $159.65 for SFM at the time of writing.
<h3>Sprouts Farmers Market's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753741820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Sprouts Farmers Market Stock In The Last 10 Years

UBS analyst Spiro Dounis maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Buy and raises the price target from $141 to $143.

UBS Maintains Buy on Phillips 66, Raises Price Target to $143

UBS analyst Mark Carden maintains The Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) with a Buy and raises the price target from $68 to $72.

CHEF

UBS Maintains Buy on The Chefs' Warehouse, Raises Price Target to $72

UBS analyst Leonardo Olmos maintains America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) with a Neutral and raises the price target from $20.4 to $21.1.

UBS Maintains Neutral on America Movil, Raises Price Target to $21.1

UBS analyst John Hodulik maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Neutral and lowers the price target from $425 to $355.

CHTR

UBS Maintains Neutral on Charter Communications, Lowers Price Target to $355

UBS analyst Brian Meredith maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Neutral and lowers the price target from $304 to $292.

UBS Maintains Neutral on Chubb, Lowers Price Target to $292

UBS analyst A.J. Rice maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Neutral and lowers the price target from $45 to $31.

UBS Maintains Neutral on Centene, Lowers Price Target to $31

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.28 per share. This is a 7.69 percent increase over earnings of $0.26 per share from the same period last year. The company reported $34.038 million in sales this quarter. This is a 2.81 percent decrease over sales of $35.021 million the same period last year.

Earnings

CORRECTION: National Research Q2 Adj. EPS $0.28 Up From $0.26 YoY, Sales $34.038M Down From $35.021M YoY

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $140 to $136.

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $136

Celestica Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) reported financial results for the second quarter on Monday after the bell. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/07/g46673477/celestica-announces-second-quarter-2025-financial-results">supply chain solutions company&#8217;s report</a>.
<ul class="wp-block-list">
<li>Q2 Revenue:&nbsp;$2.89 billion, versus&nbsp;<a href="http://benzinga.com/quote/CLS/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $2.65 billion</li>
<li>Q2 Adjusted EPS: $1.39, versus estimates of $1.22</li>
</ul>
Find out how CLS stock is currently doing: <a href="https://www.benzinga.com/quote/CLS" target="_blank" rel="noreferrer noopener">See the chart here.</a>
Total revenue was up 21% on a year-over-year basis, bolstered by &#8220;strong&#8221; adjusted operating margin.
Celestica said it repurchased 600,000 shares of its common stock for $40 million in the quarter. The company ended the period with $313.8 million in cash and cash equivalents.
&#8220;With our strong first half results, and a strengthening demand&nbsp;outlook&nbsp;from our CCS customers, we are increasing our full-year 2025&nbsp;outlook,&#8221; said Rob Mionis, president and CEO of Celestica.
Guidance:&nbsp;Celestica guided for third-quarter revenue of $2.88 billion to $3.13 billion versus estimates of $2.77 billion. The company expects third-quarter adjusted earnings to be in the range of $1.37 to $1.53 per share, versus&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;estimates of $1.28 per share.
Celestica also raised its full-year 2025 outlook. The company now expects 2025 revenue of $11.55 billion, up from prior guidance of $10.85 billion. Celestica sees adjusted earnings of $5.50 per share, up from prior guidance of $5 per share. According to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates, analysts are looking for revenue of $10.95 billion and earnings of $5.02 per share. 
CLS Price Action: <a href="http://benzinga.com/quote/cls" target="_blank" rel="noreferrer noopener">Celestica shares</a> were up 10.17% in after-hours Monday, trading at $191 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46674619/cadence-design-systems-beats-q2-earnings-estimates-raises-fy25-outlook-citing-broad-based-strength-ai-tailwinds">Cadence Design Systems Beats Q2 Earnings Estimates, Raises FY25 Outlook Citing &#8216;Broad-Based Strength,&#8217; AI Tailwinds</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.com

Guidance

Global

After-Hours Center

Movers

Celestica Stock Surges On Q2 Earnings Beat, Company Raises 2025 Outlook On 'Strengthening' Demand

UBS analyst Ashwani Verma maintains Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Neutral and raises the price target from $17 to $18.

IMVT

UBS Maintains Neutral on Immunovant, Raises Price Target to $18

UBS analyst Damian Karas maintains A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) with a Neutral and raises the price target from $74 to $76.

UBS Maintains Neutral on A.O. Smith, Raises Price Target to $76

UBS analyst Timothy Arcuri maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and raises the price target from $150 to $210.

UBS Maintains Buy on Advanced Micro Devices, Raises Price Target to $210

Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares were halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a <a href="https://www.benzinga.com/pressreleases/25/07/b46675040/fda-informs-sarepta-that-it-recommends-that-sarepta-remove-its-pause-and-resume-shipments-of-elevi">voluntary hold for Elevidys</a>.
What Happened: The FDA announced late Monday that it recommended lifting the voluntary hold on Sarepta Therapeutics&#8217; gene therapy for Duchenne Muscular Dystrophy.&nbsp;The company said in a statement that it was notified by the FDA on Monday and plans to resume shipping Elevidys&nbsp;to sites of care for treatment of ambulatory patients with Duchenne &#8220;imminently.&#8220;
The news comes after the FDA announced on Friday that it was investigating the <a href="https://www.benzinga.com/news/fda/25/07/46657622/fda-probes-death-of-8-year-old-who-received-sareptas-elevidys">death of an 8-year-old</a> in Brazil who had received Elevidys. Sarepta said the FDA determined the death was unlikely to be related to treatment with Elevidys, which is the only approved gene therapy for Duchenne.
&#8220;Last week, at the suggestion of FDA, Sarepta made the difficult decision to pause shipments of ELEVIDYS to provide the FDA with an opportunity to complete a review of available safety information. We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of ELEVIDYS for ambulatory patients,&#8221; said Doug Ingram, CEO of Sarepta Therapeutics.
Sarepta said Elevidys treatment for&nbsp;non-ambulatory patients remains on pause pending the outcome of upcoming discussions with the FDA regarding the company&#8217;s approach to risk-mitigation. 
SRPT Price Action: <a href="http://benzinga.com/quote/SRPT">Sarepta shares</a> closed Monday up 16.18% at $13.86. The stock was briefly halted after-hours. Shares were up 50.57% at $20.87 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46665188/revvity-slashes-outlook-as-china-policy-deals-diagnostics-blow">Revvity Slashes Outlook As China Policy Deals Diagnostics Blow</a></li>
</ul>
Photo: Shutterstock.

Comments

Enlightify

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL